TICH 2 Trial

Tranexamic Acid for Hyperacute Primary IntraCerebral Haemorrhage

Aim

To assess whether tranexamic acid is safe and reduces death and dependency after hyperacute (within 8 hours of onset) spontaneous intracerebral haemorrhage.

Trial Design

A phase III prospective pragmatic double blind randomised placebo controlled trial

Chief Investigator

Dr Nikola Sprigg (Medical expert) Clinical Associate Professor, University of Nottingham

Principal Investigator

Professor Rustam Al-Shahi Salman, Professor of clinical neurology, University of Edinburgh & NHS Lothian

Local lead in ED

Dr Matt Reed is the local contact for recruitment of ED patients into the study.

Research Team

  • EMERGE Research team
  • Stroke Research Group

Eligibility criteria (summary)

Patients who present to the ED within 8 hours of acute spontaneous intracerebral haemorrhagic stroke.

Further information

For more information please refer to main trial website

Status: closed

Start Date

October 2013

Coordinated by

University of Nottingham

Main Trial Site

http://tich-2.org

End date

February 2018